Nautilus Biotechnology (Nautilus Biotechnology) Operating Cash Flow per Share : $-0.44 (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Nautilus Biotechnology Operating Cash Flow per Share?

Nautilus Biotechnology's operating cash flow per share for the three months ended in Mar. 2024 was $-0.13. Nautilus Biotechnology's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.44.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -54.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Nautilus Biotechnology's Operating Cash Flow per Share or its related term are showing as below:

NAUT' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -54.2 Med: -54.2 Max: -54.2
Current: -54.2

During the past 4 years, Nautilus Biotechnology's highest 3-Year average Operating Cash Flow per Share Growth Rate was -54.20% per year. The lowest was -54.20% per year. And the median was -54.20% per year.

NAUT's 3-Year OCF Growth Rate is ranked worse than
90.51% of 1233 companies
in the Biotechnology industry
Industry Median: 3.3 vs NAUT: -54.20

Nautilus Biotechnology Operating Cash Flow per Share Historical Data

The historical data trend for Nautilus Biotechnology's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nautilus Biotechnology Operating Cash Flow per Share Chart

Nautilus Biotechnology Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

-0.11

-0.47

-0.37

-0.41

Nautilus Biotechnology Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Operating Cash Flow per Share	Get a 7-Day Free Trial											-0.10	-0.11	-0.09	-0.11	-0.13

Competitive Comparison of Nautilus Biotechnology's Operating Cash Flow per Share

For the Biotechnology subindustry, Nautilus Biotechnology's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nautilus Biotechnology's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nautilus Biotechnology's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Nautilus Biotechnology's Price-to-Operating-Cash-Flow falls into.

Nautilus Biotechnology Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Nautilus Biotechnology's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-51.711	/	124.919
	=	-0.41

Nautilus Biotechnology's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Mar. 2024 )	=	Cash Flow from Operations (Q: Mar. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
	=	-16.266	/	125.135
	=	-0.13

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.44

Nautilus Biotechnology Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Nautilus Biotechnology's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Nautilus Biotechnology (Nautilus Biotechnology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nautilus Biotechnology Inc (NAS:NAUT) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

2701 Eastlake Avenue East, Seattle, WA, USA, 98102

Website

https://www.nautilus.bio

Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. It has built a prototype of a single-molecule instrument, Proteomic Analysis System.

Executives

Michael Seth Altman	director	C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Subramanian Sankar	officer: Senior VP, Product Development	C/O NAUTILUS BIOTECHNOLOGY, INC., 201 INDUSTRIAL RD. #310, SAN CARLOS CA 94070
Gwen E Weld	officer: Chief People Officer	C/O ISILON SYSTEMS, INC., 3101 WESTERN AVENUE, SEATTLE WA 98121
Anna Mowry	officer: CFO and Treasurer	C/O NAUTILUS BIOTECHNOLOGY, INC., 201 INDUSTRIAL RD. #310, SAN CARLOS CA 94070
Matthew B. Murphy	officer: General Counsel	C/O NAUTILUS BIOTECHNOLOGY, INC., 425 PONTIUS AVE N, STE 202, SEATTLE WA 98109
Sujal M Patel	director, 10 percent owner, officer: CEO, President, and Secretary	C/O ISILON SYSTEMS, INC., 3101 WESTERN AVENUE, SEATTLE WA 98121
Mary E. Godwin	officer: Senior VP, Operations	3101 WESTERN AVENUE, SEATTLE WA 98121
Karen Akinsanya	director	SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc	director	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Matthew L. Posard	director	11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Matthew S Mcilwain	director	1000 SECOND AVENUE, SUITE 3700, SEATTLE WA 98104
Benjamin A Horowitz	10 percent owner	2865 SAND HILL ROAD #101, MENLO PARK CA 94025
Marc L Andreessen	10 percent owner	C/O ARNOLD & PORTER LLP, 3 EMBARCADERO CENTER 7TH FLOOR, SAN FRANCISCO CA 94111